As the world aspires to return to normal life after more than a year of living through a pandemic, nations are racing to deliver vaccines that can slow – and hopefully stop – the spread of Coronavirus.
Doing so successfully will depend on a variety of factors, from producing and shipping billions of doses, ensuring that Rich countries are not monopolies The world’s supply of vaccines, and importantly, actually getting dosage into everyone’s arms.
The charts and maps below will update to show the most recent data about the largest vaccination rollout in history, in the US, and globally.
There are notable interstate differences in the rate at which vaccinations are given to citizens.
The first two vaccines approved for emergency use in America, developed by companies Pfizer / BioNTech and Modern, designed for injection of two doses spaced several weeks apart. The Johnson & Johnson Vaccines allowed for use by the end of February require only one dose. So to vaccinate everyone in the US would ultimately mean injecting 100 to 200 doses per 100 people per state and territory – or a total of 330 million to 660 million doses for nationwide. It is a big logistical challenge.
U.S. vaccine rollout started more slowly than expected. The Trump administration set a target of bringing 20 million vaccinations by the end of 2020. That goal was not reached until the end of January. In early March, President Joe Biden said the United States would have enough vaccines for all adults at the end of May – two months earlier than the plan of his administration earlier. However, there are concerns that the vaccination site is getting poorer Everybody and community of color behind.
Search or navigate through this table to see how your state or territory is doing on these important vaccine deployments.
Vaccine release process
This chart shows the number of vaccines that have been vaccinated per 100 people per state since the beginning of 2021. The top three states and the number of US countries are highlighted. Enter the name of any other US state or territory in the search bar and choose to add it to the chart.
This chart shows the number of daily doses of vaccine administered to everyone nationwide since early 2021. Due to the spike in data due to delayed reporting, the line showing the average number of doses over the 7 days is provided. for a clearer idea of whether the rollout is accelerating or slowing down.
Deploy vaccines by country
More countries appear on this map showing vaccine doses given per 100 people because these numbers are more widely reported.
The US is ahead of most other countries in vaccine deployment. But among the major countries, Israel is original leadership.
Search or navigate through this panel to see how each country is performing. It revealed that a number of countries were already implementing different strategies: the UK, for example, decided to give as many people their initial dose, delaying their second injection.
Vaccine release process
This chart shows how many vaccines have been vaccinated per 100 people per country since the beginning of 2021. Enter the name of any country in the search bar and choose to compare that country’s timeline with the United States. and the other three leading countries for vaccine rollout worldwide. Only countries that have begun immunization campaigns will emerge.
This chart shows the number of daily doses of vaccine administered to people around the world. Due to the late reporting spike, the 7-day average dose line provided gives a clearer indication of whether the implementation is accelerating or slowing down.
The status of the top vaccines
This table records the status of top COVID-19 vaccines, displays licenses for use in the US and other markets for purchase, plus prices from information on sales agreements. edited by UNICEF, if.
Pfizer / BioNTech and Moderna vaccines, with clinical test results showing them more 90% effective in the prevention of disease, based on one new technology provides a chain of RNA that helps our cells make viral proteins that trigger immune responses.
The drawback is that these vaccines are more expensive than vaccines made by grafting genetic material from the coronavirus into a neutralized version of another virus, such as the one produced by the company. Anglo-Swedish AstraZeneca, based on research from Oxford University, Johnson & Johnsonand Russian Gamaleya Research Institute.
Other leading vaccines are based on inactivated versions of the coronavirus, a longstanding approach to vaccine making or subunits of viral proteins.
Jeremy Singer-Vine contributed to this story.